ACE2/Angiotensin-(1-7)/Mas Axis and Cardiovascular Regeneration

摘要

Abstract: Discovery of angiotensin converting enzyme (ACE)-2 provided a strong impetus for the development of novelntherapeutic tools for the treatment of cardiovascular diseases (CVDs). Angiotensin (Ang)-(1-7), the product of ACE2, vianactivation of Mas receptor elicits cardiovascular protective effects to a large extent by counter-regulating ACE/Ang-nII/AT1-receptor axis of renin angiotensin system (RAS).nBone marrow (BM)-derived progenitor cells play an important role in cardiovascular homeostasis. Angiogenic precursorncells (APCs) have received tremendous attention in the recent years for their therapeutic application for treatment ofnCVDs, where cardiovascular tissue regeneration is the desired outcome. Autologous cell therapy is a better treatmentnoption for patients with cardiovascular complications. However, circulating APCs from these patients are dysfunctionalnlimiting their therapeutic utility. Thus ex vivo modification to restore their regenerative potential is essential to improvenoutcomes of autologous cell therapies in CVD.nMembers of both pathological and protective axes of RAS have been identified in one or more types of BM-derived cells.nModulation of the function of APCs by Ang-II or Ang-(1-7) has now been implicated in the pathology and protection ofncardiovascular systems, respectively. Thus, novel functions of RAS in the cardiovascular regenerative physiology andnpharmacology are being unraveled. Accumulating evidence points to the ACE2/Ang-(1-7)/Mas axis as a promising targetnfor the treatment of CVDs. The major focus of this review is to highlight the protective role of ACE2/Ang-(1-7)/Masnpathway in the reparative function of BM-derived cells for cardiovascular repair and regeneration.